Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Eva L. Feldman"'
Autor:
Timothy Fullam, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Morgan Beauchamp, Michael Benatar, Tulio Bertorini, Robert Bowser, Mark Bromberg, Javier Mascias Cadavid, Gregory T. Carter, Mazen Dimachkie, Dave Ennist, Eva L. Feldman, Terry Heiman-patterson, Sartaj Jhooty, Isaac Lund, Christopher Mcdermott, Gary Pattee, Dylan Ratner, Paul Wicks, Richard Bedlack
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. :1-5
Autor:
Yuyao Sun, Paul Barkhaus, Benjamin Barnes, Morgan Beauchamp, Michael Benatar, Tulio Bertorini, Mark Bromberg, Gregory T. Carter, Jesse Crayle, Merit Cudkowicz, Mazen Dimachkie, Eva L. Feldman, Timothy Fullam, Terry Heiman-Patterson, Sartaj Jhooty, Isaac Lund, Christopher Mcdermott, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Paul Wicks, Richard Bedlack
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. :1-5
ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review ozone therapy. Ozone therapy has possible mechanisms for slowing ALS progression based on its antioxidant, anti-infl
Autor:
Stephen A. Goutman, Jonathan Boss, Christopher Godwin, Bhramar Mukherjee, Eva L. Feldman, Stuart A. Batterman
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24:219-229
To identify associations between occupational settings and self-reported occupational exposures on amyotrophic lateral sclerosis (ALS) survival and phenotypes. All patients seen in the University of Michigan Pranger ALS Clinic were invited to complet
Autor:
Jiacong Du, Jonathan Boss, Peisong Han, Lauren J. Beesley, Michael Kleinsasser, Stephen A. Goutman, Stuart Batterman, Eva L. Feldman, Bhramar Mukherjee
Publikováno v:
J Comput Graph Stat
Penalized regression methods are used in many biomedical applications for variable selection and simultaneous coefficient estimation. However, missing data complicates the implementation of these methods, particularly when missingness is handled usin
Publikováno v:
Amyotroph Lateral Scler Frontotemporal Degener
We present a composite endpoint that can be used in amyotrophic lateral sclerosis (ALS) trials, which combines functional status (via the ALS functional rating scale) and survival, denoted ALS/SURV. ALS/SURV modifies and extends the combined assessme
Publikováno v:
Expert Opin Investig Drugs
INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of cortical, brainstem, and spinal motor neurons; it causes progressive muscle weakness and atrophy, respiratory failure and death. No currently available treatment eith
Publikováno v:
Amyotrophic Lateral Sclerosis. 13:229-232
The multidisciplinary approach to treatment of amyotrophic lateral sclerosis (ALS) has improved the overall care of patients suffering from this disease ( 1 , 2 ). This approach typically has included neurologists, physiatrists, occupational therapis
Publikováno v:
Amyotrophic Lateral Sclerosis. 10:63-73
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects both upper and lower motor neurons (MN) resulting in weakness, paralysis and subsequent death. Insulin-like growth factor-I (IGF-I) is a potent neurotrophic f
Publikováno v:
Amyotrophic Lateral Sclerosis. 7:96-99
Non-invasive positive pressure ventilation (NIV) treatment of advanced respiratory insufficiency prolongs survival in ALS. To investigate the critical question of whether earlier initiation of NIV might provide additional benefit, a randomized trial
Publikováno v:
Autophagy. 6:819-820
Phosphoinositides (PIs) are a group of low-abundance phospholipids that play a critical role in the control of organelle and membrane traffic. There is strong evidence that specific PIs are also important for the regulation of autophagy. PIs are modi